Sophia Genetics SA

NASDAQ SOPH

Data sourced from

and

Daily

Download Data

Sophia Genetics SA Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024

Sophia Genetics SA Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

Sophia Genetics SA 52-week high Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Sophia Genetics SA 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Sophia Genetics SA average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.

NASDAQ: SOPH

Sophia Genetics SA

CEO	Dr. Jurgi Camblong M.B.A., Ph.D.
IPO Date	July 23, 2021
Location	Switzerland
Headquarters	Rue du Centre 172, Saint-Sulpice, Switzerland, 1025
Employees	430
Sector	Healthcare
Industry	Health information services

Description

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Key trends